A probiotic way to lower cholesterol, and triglycerides levels: Probiotic Lactobacillus Gasseri SBT 2055 (LG2055) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 5/October/2018, 10.27 pm

Molecular therapy for inflammation and arthritis:  Lidocaine (brand name: xylocaine and lignocaine), a drug used to treat numb tissue and ventricular tachycardia, increases IL-9 levels, augments proliferation of ILC2s (type 2 innate lymphoid cells) and regulatory T (Treg) cells, promotes resolution of inflammation, attenuates cartilage destruction, decreases bone loss, and inhibits pathological features associated with arthritis, via up-regulation of its target genes, 4/October/2018, 6.41 pm
October 4, 2018
A probiotic way to stay free of diabetes: Probiotic Lactobacillus gasseri-based therapy for body weight control, energy homeostasis and TIIDM: Probiotic Lactobacillus gasseri inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up-regulation of its target gene, 5/September/2018, 10.46 pm
October 5, 2018
Show all
0
Published by admin_auro at
Categories
Tags

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.

Research findings to Therapeutic opportunity:

This study suggests, first the first time, a Lactobacillus Gasseri SBT 2055 (LG2055)-based therapy for lowering cholesterol and triglyceride levels and to treat Non-alcoholic fatty liver disease (NAFLD). Lactobacillus Gasseri SBT 2055 (LG2055) has been shown to protect against irritable bowel syndrome. However, the mechanism of action remains largely unknown.

Lactobacillus Gasseri, by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus,  Lactobacillus Gasseri SBT 2055 (LG2055, either alone or in combination with other drugs, may be used to treat NAFLD.

Figure 1. Mechanistic insights into how  Probiotic Lactobacillus Gasseri SBT 2055 (LG2055) decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

Figure 2. Probiotic Lactobacillus Gasseri SBT 2055 (LG2055) functions as a cholesterol-lowering agent. Lactobacillus Gasseri SBT 2055 (LG2055) lowers cholesterol and triglyceride levels and attenuates NAFLD through down-regulation of HMGCR

[easy_payment currency=”USD”]

 

 

 

 

 

 

 

 

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does  Lactobacillus Gasseri SBT 2055 (LG2055) decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., A probiotic way to lower cholesterol, and triglycerides levels: Probiotic Lactobacillus Gasseri SBT 2055 (LG2055) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 5/October/2018, 10.27 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

admin_auro
admin_auro

Related posts

August 23, 2019

The Mechanistic basis of how Liraglutide mitigates complications of diabetes and obesity:  Liraglutide (trade name: Victoza, Saxenda), a Glucagon-like peptide-1  (GLP-1) receptor agonist,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 24/August/2019, 12.27 am

Read more
August 23, 2019

Natural product-based anti-ageing and Lifespan extension therapy: A pharmaceutical mixture encompassing Curcumin and Dasatinib (CAD)  increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene, 24/August/2019, 12.05 am

Read more
August 23, 2019

Combinatorial therapy for autoimmune diabetes  (TIDM):   A pharmaceutical mixture encompassing Dulaglutide (trade name: Trulicity), a Glucagon-like peptide-1  (GLP-1) receptor agonist, and Verapamil (brand name: Calanm, Isoptin and others), an anti-hypertensive drug,  increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 23/August/2019, 11.38 pm

Read more

Comments are closed.